Amgen Inc. closed $13.93 short of its 52-week high ($346.85), which the company reached on July 25th.

False Claims Act suit alleging that medical practices engaged in a scheme to overbill Medicare for Amgen Inc. drugs is now dismissed, a New York federal district court said.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Shares of Amgen Inc. AMGN slumped 0.73% to $332.80 Tuesday, on what proved to be an all-around mixed trading session for the ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...

In a report released today, Michael Yee from Jefferies assigned a Buy rating to Amgen (AMGN – Research Report), with a price target of ...

An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...

With a sold-out crowd and a ton of momentum, Rory McIlroy appeared poised to post his first DP World Tour victory on Northern ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The ...

Amgen will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney ...

Amgen has long been committed to producing treatments that help people dealing with ailments, but for the past 34 years, it ...

Rory McIlroy is on familiar soil. Eleven days after a tie for ninth in the Tour Championship, McIlroy fired a first-round 68 ...